CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

Merck’s executive director, operations lead, global medical affairs and outcomes research discusses how data is helping to ...

VectorY Therapeutics partners with Shape Therapeutics to advance innovative therapies for neurodegenerative diseases using ...

Former CDC director Susan Monarez raises alarms about potential changes to childhood vaccine schedules, warning of increased ...

Roche strengthens its pipeline by acquiring 89bio and its promising MASH treatment, Pegozafermin, enhancing options for ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...

HOSP focuses on advocacy, collaboration, and best practice sharing to enhance health system specialty pharmacies and improve ...

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and ...

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.